Can a short treatment course cure most cases of acute hepatitis C?

When someone is newly infected with hepatitis C, the clock starts ticking. The goal is to clear the virus before it can cause lasting liver damage. A new study looked at whether a shorter, two-month treatment could do just that. The research followed 286 adults who had never been treated for hepatitis C before and had a recent, acute infection. They all received an 8-week course of a combination pill called glecaprevir/pibrentasvir. The main question was: would the virus stay gone? The answer, for most, was yes. Twelve weeks after finishing treatment, 96.2% of participants had no detectable virus in their blood, which is considered a cure. For those who stuck with the treatment for reasons not related to the virus itself, the cure rate was 100%. The treatment was generally safe. A small percentage of people had serious side effects, but none were linked to the medication. No one's liver function got worse during treatment, and many saw improvements. It's important to remember this was a single-group study. Everyone got the same treatment, so we don't know how it stacks up against other options or doing nothing. The group also included a significant number of people who also had HIV or were recent injection drug users, which might affect how the results apply to everyone.